Влияние компенсации углеводного обмена и терапии ингибиторами ГМГ-КоА-редуктазы на факторы риска атеросклероза при сахарном диабете 2-го типа
Диссертация
На основании результатов проведенных исследований были сделаны следующие выводы: t Нарушения лнпндного обмена выявлены у 98% пациентов с СД 2 типа, при этом 42,4% пациентов имеет комбинированную днепннндемню. проявляющуюся в виде повышения уровня ХС-ЛПНП и ТГ в сочетании со снижением уровня ХС-ЛПВП, Показатели лнпндного спектра практически у половины пациентов соответствуют высокому риску… Читать ещё >
Список литературы
- Аронов Д.М. Снмвастатнн. Новые данные и перспективы, М., 2002,
- Долгов В.В., Титов В.Н, Таорогова М. Г. н др. Лабораторная диагностика нарушения обмена лкпидов (учебное пособие для врачей). -М&bdquo- РМАПО, 1999.
- Дедов ИЛ, Шесгакова М. В, Максимова М. А. Федеральная целевая программа «Сахарный диабет» (методические рекомендации), М., 2002,
- Лнповецкнй Б.М. Клиническая лнпндологня. Санкт-Петербург., 2000.
- Мари Р., Греинер Д., Мейес П., Родуэлл В. Биохимия человека. М&bdquo- 1993.
- Шевченко О. П, Шевченко А-П. Статнны — ингибиторы ГМГ- КоА-релуктаэы. М., 2003,
- Adkins J.C., Faulds D, Micronised fenofibrate: a review of its properties and clinical efficacy in the management of dyslipidemia. // Drugs. 1997. -Vol, 54. — P. 615−633.
- Alexandridis O., Pappas G-, Elisaf M. Rhabdomyolysis due lo combination therapy with cervislatin and gemfibrozil. И Am J Med. 2000. -Vol. 109.-P. 261'262,
- American Diabetes Association. Management of dysiipidemia in adults with diabetes (position statement), // Diabetes Care. 2002. — Vol, 25 (suppl.). -P, 74−77.
- American Diabetes Association. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and relatedcomplication (position statement). U Diabetes Care. 2002. — Vol. 25 (suppl,), -P 50- 60.
- American Diabetes Association. Diabetes mellitus and exercise (position Statement). // Diabetes Care. 2001. — Vol. 24 (suppl.). — P. 51−55.
- Aogulo P, Nonatcoholik fatty liver disease. U N Engl J Med. 2002. Vol 346,-P, 1221−1231,
- Apstcin C. S, Glucose-insulin-potassium for acute myocardial infarction: rcmarfcbie results from a new prospective randomised trial, ft Circulation. 1998, — Vol. 98. — P. 2223 2226.
- Assmann G, Schuhe H, Identification of individuals at high risk for myocardial infarction, it Atherosclerosis. 1994. — Vol, 110. — P. 11−21.
- Bayncs J.W. Role of oxidative stress in development of complications in diabetes. //Diabetes, 199J. — VoJ. 40. — P 405−412.
- Beaton SJ-" Nag S.S., Gunter M.G., et al. Adequacy of gtycemic, lipid and blood pressure management in patient with diabetes in a managed care setting. //Diabetes Care, 2004. — Vol. 27. — P, 694−698.
- Bierman E.L. George Lyman Duff Memorial Lecture. Atherogenes in diabetes. // Arterioscler Thromb. 1992. — Vol. 12, — P. 647−656.
- Blake G, D.+ Ridker P.M. Inflammatory bio-markers and coronary risk prediction. // J Intent Med. 2002. — Vol. 252. — P. 283−294.
- Blake GD., Ridker P.M. Are statins anti-inflammatory? // Curr Control Trials Cardiovasc Med. 2000. — Vol. 1. — P. 161−165.
- Brown M.S., Goldstein J.L. Lipoprotein metabolism in macrofag: implication for cholesterol ddeposiiion in atherosclerosis. // Ann Rev Biochem. -1983 -Vol. 52, P. 223 — 228.
- Brown W, V" Dujovne C-L-, Farquhar J. W, ct al. Effects of fenofibrate on plasma lipids, Doubie-blind, multrcenter study in patients with type f/A or IIB hyperlipemia. // Arteriosclerosis. 1986, — Vol. 6. — P- 670−678.
- Brown lee M, Lilly Lecture 1993. Glycation and diabetic complications, // Diabetes 1994. — Vol. 43, — P. 836−841,
- BuckeU L., Ballard P., Davidson R, el al. Selectivity of 2D4522 for inhibition of cholesterol synthesis in hepatic versus nonhepatic cells. // Atherosclerosis. 2002. — Vol. 151 — P. 41 — 44.
- Caixas A-, Ordonez-Llanos J., Leiva A., et al. Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. // Diabetes. 1997r — Vol. 46. — P. 1207−1213.
- Castelli WJ. Lipids, risk factors and ischemic heart disease. U Aterosclcrosis. 1996. — Vol. 124 (suppl.) — P. 1−9,
- Chapman M J., Gudrin M, Bruckert E, Atherogenic, dense low-density lipoproteins: Pathophysiology and new therapeutic approaches. // Eur Heart J -1998. Vol J 9 Suppl A., — P. 24−30,
- Chen Y.D., Swami S., Skowronski M" et al. Differences in postprandial lipemia between patients with normal glucose tolerance and noninsulindependent diabetes mellitus, // J Clin Endocrinol Melab, 1993. — Vol. 76, — P. 172−177.
- Cressman M. D, Hoogwcrf BJ. HMG -CoA r c d u c las e inhibitors. A new approach to the management of hypercholesterolemia, ti Clcve Clin J Mcs. — 1998. — Vol. 55.-P, 93−110.
- Curb J.D., Abbott R.D. C-rcactive protein and future risk of thromboembolic stroke in healthy men, H Circulation, 2003. — Vol. 107. — P. 2016−2020.
- Danesh J., Whincup P" Walker M. Low grade inflammation and coronary heart disease: prospective study and updated meta-analysis. U BMJ. 2000. -Vol. 321, P. 199−204.
- Davis W.A., Knuiman M.V., Hendrie D.(el al. Determinants of diabetes-attributable non-blood glucose-lowering medication costs in type 2 diabetes. II Diabetes Care. 2005. — Vol. 28. — P. 329−336.
- Dc Graaf }., l. cmmcrs H.L.M., Hectors M.P.C., et al, Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subtraction in healthy subjects. II Arterioscler Thromb 1991. — Vol. 11. — P. 198−206.
- Edward T.H., Yeh J.T., Willerson S.A. Coming of age of C-reactive protein. Using inflammation markers in cardiologj'. tl Circtriation 2003. -Vol. 107. — P.370−375,
- Edgar A.D., Tomkiewicz C. t Coslet P., et al. Fcnofibrate modifies transaminase gene expression in peroxisome proliferator activated receptor alpha-dependent pathway, // Toxicol Lett. 1998. — Vol. 98, P. 13−23.
- Erdman D.M., Cook C.B., Grccnlund KJ. t et al. The impact of outpatient diabetes management on serum lipids in urban african-americans with type 2 diabetes, II Diabetes Care, 2002, — Vol. 25. — P. 9−15,
- Ericsson C.G., Hamsten A., Nilsson J, et al. Angiographic assessment of effects of bezaflbrate on progression of coronary artery disease in young male post infarction patients. II Lancet. 1996, — Vol. 347. — P.849−853.
- Famier M., Bonnefous F" Debbas M. t et al. Comparative efficacy and safety of micronized fcnofibrate and simvastatin in patients with primary type lia or lib hyperlipemia, U Arch Intern Med. 1994. — Vol. 154. — P.441 -449.
- Famier M" Picard S. Diabetes: statins, fibrates, or both? II Curr Atheroscler Rep. 2001. — Vol 3. — P. 19−28.
- Frayn K.N. Insulin resistanse and lipid metabolism. HCurr Opin Lipidol- -1993,-Vol, 5.- P. 197−204.
- Fruchart J.C., Staels B" Duriez P. PPAR-a, metabolic disease and atherosclerosis. // Pharmacol Res. 2001. — Vol. 44. — P. 345−352.
- Fruchart J.C., Staels B, Duriez P. The role of fibric acids in atherosclerosis. U Curr Atheroscler Rep. 2001. — Vol. 3, P. 83−92.
- Ga-dc P., Pcdersen O. Intensive Integrated Therapy of Type 2 Diabetes- Implications for Long-Term Prognosis. H Diabetes, 2004. -Vol, 53. — P. 3947.
- Giugliano D, Ccriello A., Paolisso G- Oxidative stress and diabetic vascular complications. II Diabetes Care. 1996. — Vol. 19, — P. 257−267,
- Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin 5963 people with diabetes: randomized placebo-controlled trial. // LanceL 2003, — Vol. 361. — P. 20 052 016.
- Hillier T.A., Pedula KX. Characteristics of the adult population with newly diagnosed type 2 diabetes. II Diabetes Care. 2001. — Vol. 24. — P. 15 221 527.
- Howard B, W. Lipoprotein metabolism in diabetes mellitus. /1J Lipid Res. -1987. Vol.28. — P. 613−628.
- Hu G-, Jousilahli P., Noel C-, et al. Physical activity, cardiovascular risk factors and mortality among finnish adults with diabetes. It Diabetes Care. 200S. Vol. 28, — P. 799−805,
- Hsu L, Spinier S.A. Comparative evaluation of the safety and efficacy of HMG-CoA¦ reductase inhibitors monotherapy in the treatment of primary hypercholesterolemia. // Ann Pharmacol. 1995. — Vol. 29. — P. 743−759.
- Ikeda IL, Shimada K. Statin and monocytes (letter). // Lancet, 1999, -Vol. 353. — P. 2070.
- Jager A., van Hinsbergh V.W., Kostense P.J., et a! Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects- the Hoom study. //Arterioseler Thromb Vase Biol, 1999, — Vol, 19. -P. 3071−3078.
- Jones P" Davidson M, Stein E., et al. Comparison of the efficacy and safety of rosuvastatin versus acorvastatin, simvastatin and pravastatin across doses (STELI AR Trial). // Am J Cardiol. 2003. — Vol. 93 P. 152−160.
- Kannel W. B, McGee D, L. Diabetes and glucose tolerance as risk factors for cardiovascular disease- the Framingam Study. // Diabetes Care, -1979.-Vol.2,-P, ?20−126.
- Kannel W.B. Lipids, diabetes and coronary heart disease insights from Framingam Study, // Am Heart J, 1985. — Vol. 110. — P. IIOO-1107,
- Koba S. t Hirano T, f Yoshino G, et al, Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes. //Atherosclerosis, 2002, -Vol. 160.-P. 249−256.
- Kiortsts D.N., MiHonis H., Bairaktari E" et al. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidcmia, // Eur Clin Pharmacol. 2000. — Vol. 56. — P. 631−635.
- Kirchgassler K.J., Schmitz H., Bad G, Effectiveness and tolerability of 12-week treatment with micronized fenofibrate 200 mg a drug-monitoringprogramme involving 9884 patients with dyslipidaemia. // Clin Drug Invest, -1998.-Vol, I5--P- 197−204,
- Krolcwski A.S., Warram J.H., Valsania P., ct al. Evolving natural history of coronary heart disease in diabetes mellitus, // Am J Med, 1991. Vol 90. -P.56−61.
- Laakso M. Cardiovascular risk factors in type 2 diabetes mellitus- Finnish study. // Diabetes Care. 2002. — Vol. 25. — P. 318−324.
- Malmstrom R. t Packard CJ" Watson T.D., ct al. Metabolic basis of hypotriglyceridic effects of insulin in normal men, // Arterioscler Thromb Vase Biol 1997. — Vol. 36. — P. 742*754.
- Malmstrom R." Packard C.J., Watson T.D., ct al Defective regulation of triglyceride metabolism by insulin in the liver in noninsu I in-dependent diabetes meltitus. II Diabetologia. 1997. — Vol. 40. — P. 454−462.
- S3. Mai mend ier C.L., Deicrofx C. Effects of fenoflbrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. // Atherosclerosis. 1985, — Vol. 55. — P. 161−169.
- McFarlanc LT Jacobcr SJ-, Winer N, et at. Control of cardiovascular risk factors in patients with diabetes and hypertension al urban academic medical centers. II Diabetes Care. 2002. — Vol. 25. — P 718−723.
- Miller D. B, Spencc D.B. Clinical pharmacokinetics of fibrtc acid derivatives (fibratcs), U Clin Pharmacokinct. 1998. -Vol. 14. P. 156−162.
- Munoz A., Gutchard J .P., Reginault P.H. Micronixed fenofibrate. // Atherosclerosis. 1999 — Vol. 110, — P 45−54,
- National Institute of Diabetes and Digestive and Kidney disease: diabetes in America. 2^ ed. 1995.
- Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S., et al- Elevated levels of authentic plasma hydroperoxides in NIDDM- H Diabetes. 1995. -Vol, 44.-P. 1054−1058.
- Nourooz-Zadeh J" Rahimi A., Tajaddini-Sarmadi J., et al. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. // Diabetotogia. 1997. — Vol. 40. P. 647−653,
- Pasccri V. Chang J., Willerson J.T., et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by antiatherosclerotic drugs. (i Circulation. 2001. — Vol. 103.1. P 2531−2534.
- Poulter N. The impact of micronized fenofibrate on lipid subfractions and on reaclung HDL-Utrgcts in 7,098 patients with dyslipidaemia. II Br J Cardiol -1999.-Vol. 6.-P. 682−685.
- Rash id S., Barrett HJt, UlTelman K, D. T et al. Ltpolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation, H Arterioscler Thromb Vase Biol, 2002, — Vol 22. — P. 483−487.
- Reaven G.M. Banting lecture: role oi insulin resistance in human disease, tt Diabetes 1988. — Vol. 37. — P. 1595−1607.
- Ridker P.M., Cushman M., Stampfcr M.J. r et at. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. // Circulation. 1998. — Vol. 97. — P. 425−428.
- Ridker P.M., Rifai N. Pfeffer M-. et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. // Circulation 2000. — Vol. 101 — P. 2149−2153,
- Rittcr J.L., Nabulsi S. Fenofibrate-induced elevation in serum creatinine.// Pharmacotherapy. -2001.- Vol. 21,-P, II45−1149.
- Robins SJ" Collins D" Wittcs J.T., et al. for the VA-H1T Study group. Relation of gemfibrozil treatment and Jiptd levels with major coronan' events. VA-lilT: A randomized controlled trial. // JAMA. 2001. — Vol. 285. — P. 1585-I59L
- Ross R. Atherosclerosis: an inflammatory disease. //N EngJ Med. 1999- 340: 115−26
- Saakincn P., Curb J. D" Abbott R.D., et al, C-reactivc protein and myocardial infarction. // J Clin Epidemiol. 2002, — Vol. 55- - P, 445−451.
- Sanchez P L, Morinigo J.L., Pabon P., ct al. Prognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndrome. // Heart. 2004. — Vol. 90, — P. 264−269.
- Shepherd J. Fibratcs and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety, // Eur Heart J, 1995. — Vol 16, — P. 5−13.
- Sprafka J.M., Burke G, L" Folsom A, R" et at. Trends in prevalence of diabetes mcllitus in patients with myocardial infarction and effect of diabetes on survival: the Minnesota Heart Study. // Diabetes Care. 1991- Vol. 14. — P. 537 543,
- Schoonjans K, Martin G-, Stacls B" ct al. Peroxisome proliferator-activatcd receptors, orphans with ligands and functions. // Cuit Opin Lipidol.1997,-Vol. 8,-P. 159−166.
- Stacls B., Koenig W., Habib A., et al, Activation of human aortic smooth-muscle cells is inhibited by PPARa but not by PPARy activators, U Nature.1998. Vol. 393. — P. 790−793,
- Stamler J, Vacaro O., Neaton i, D. t et al, Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial, // Diabetes Care. 1993. — Vol. 16. — P. 433−444.
- Standberg T.E., Vanhanen H., Tikkanen MJ. Eflfect of statins on C-reactivc protein in patients with coronary artery disease. // LanceL 1999. Vpl. 353. — P, 118−119.
- Stein E. A, Managing dyslipidemia in the high-risk patient. II Am J Cardiol, 2002, — Vol. 89 (suppl). — P, 50−57.
- Stem M.P. Mitchell B.D., Haffncr S.M., ct al. Docs glycemic control of type II diabetes suffice to control diabetic dyslipidemia? A community perspective. U Diabetes Care. 1992. — Vol. 15. — P, 638−644.
- Stratton I.M., Adler A.I., Neil H.A.W., ct al for the UK Prospective Diabetes Study Group. UKPDS 35- Association of Glycacmia with Macrovascular and Microvascular Complications of Type 2 Diabetes:
- Prospective Observational Study. // BMJ, 2000. — Vol. 321.-P. 405−412.
- Shultze M.B., Ritnm E.B., Lt t, et al. C-reaetive protein and incident cardiovascular events among men with diabetes, U Diabetes Care, 2004. — Vol. 27.-889−894
- Syvannc M., Hilden H., Taskinen M, R. Abnormal metabolism of postprandial lipoproteins in patients with noninsulin-dependent diabetes mellitus is not related with coronary artery disease. // J Lipid Res. 1994, — Vol. 35. — P. 15−36,
- Syvanne M., Taskinen M, R, Lipids and lipoproteins as coronary risk factors in noninsulin-dependent diabetes, // Lancet. 1997, — Vol, 350 (suppl I). ~P, 20−23.
- Taskinen MR. Hyperlipidemia in diabetes, // Clin End Metab. 1990, — Vol. 4. — P. 743−775.
- Taskinen M. R, Lipoprotein lipase in diabetes. // Diabet Metab Rev. -1987.-Vol, 3. P. 551−570.
- UK Prospective Diabetes Study (IJKPDS) Group, Risk factors for coronary artery disease in non-insutin dependent diabetes mellitus. U Diabetes Care, 2002, — Vol. 25 (suppl). — P. 74−77.
- Vaughan C.J., Gotto M.A., Qasson B.T. The evolving role of statins in the management of atheri sclerosis, // J Am Coll Cardiol, 2000. — Vol. 35- - P. 110.
- Verma S, Szmitko P.E., Yeh E.T.K C-Reaetive Protein. Structure affects function. U Circulation, 2004. — Vol. 109. — P. 1914−1917.
- Vu-Dac X., Schoonjans K., Kosykh N. r et al. Fibratcs increase human apolipoprotein A-Il expression through activation of the peroxisome proliferator-activated receptor, til Clin Invest. 1995. — Vol. 96. — p. 741−750.
- Wallidus G-, Holme 1., Junger I., et. al. High apolipoprotein B, low apolipoprotein A-l, and improvement in the prediction of fatal myocardial infarction (AMORIS Study), it Lancet. 2001. — Vol. 358, — P. 2026 — 2023.
- Wim K-, Visser C. A-, Hermens W. T^ et al. C-reaetive protein as a cardiovascular risk factor. More than an epiphenomenon?//Circulation. 1999. Vol. IOO, — P. 96−102.
- Wojciak-Stothard B., Williams I. Monosyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. // J Cell Biol. 1999. — Vol. 145. — P. 1293−1307.
- Wong B. r Luma W.C., Smith A.M., et al. Statins suppress THP-I cell migration and secretion of matrix metalloproteinasc by inhibiting geranygeranylation. // Leukoc Biol. 2001 — Vol. 69. — P. 959−962.